



**SHATTUCK**  
LABS

NEWS RELEASE

# Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023

2023-11-06

AUSTIN, TX and DURHAM, NC, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report its third-quarter 2023 financial results and provide a general business overview on Thursday, November 9, 2023.

**Title:** Shattuck Labs Third-Quarter 2023 Earnings Call

**Speakers:** Taylor Schreiber, *CEO*; Andrew Neill, *CFO*; Lini Pandite, *CMO*

**Date & Time:** Thursday, November 9, 2023 at 8:00 a.m. ET

**Dial-in Details:** Toll-Free Dial-In Number: 1 (888) 440-4368

Toll Dial-In Number: 1 (646) 960-0856

Conference ID: 5023003

**Webcast Details:** <https://events.q4inc.com/attendee/625426190>

To listen to the live webcast, please visit the Investor Relations page of the Shattuck Labs website [here](#). Participants may register for the call [here](#). While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company's website.

## **About Shattuck Labs, Inc.**

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the

development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ("ARC®"), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company's lead SL-172154 (SIRP $\alpha$ -Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

**Investor & Media Contact:**

Conor Richardson  
Vice President of Investor Relations  
Shattuck Labs, Inc.  
[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

Source: Shattuck Labs, Inc.